Context-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity
CTLA4-Ig therapies, including abatacept, are widely used in autoimmune and inflammatory disease. Oxley et al. identify the specific contexts where CTLA4-Ig binding to cell surface CD80 can release...
cell.com